ClinicalTrials.gg
RecruitingNCT07093463CONCOLUpdated Nov 6, 2026

Colon-delivered Riboflavin and Gut Microbiota Composition

An interventional study of Colon-delivered riboflavin and Conventional riboflavin in Microbiome Dysbiosis and Gut Health, sponsored by dsm-firmenich Switzerland AG. Recruiting at 1 site in Germany. Open to participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by dsm-firmenich Switzerland AG (part of dsm-firmenich) · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Study summary

Recent studies suggest B-vitamins such as riboflavin to possess prebiotic-like effects. However, there is still a lack of understanding of the exact host health benefits vs. conventional systemically available vitamin forms. The present study explores the benefit of colon-delivered vitamin B2 vs. conventional vitamin B2 in comparison to placebo in an aging population on gut microbiota and metabolic activity as well as gut health.

02

Conditions studied

  • Microbiome Dysbiosis
  • Gut Health

Browse trials for

Keywords

  • elderly
  • microbiome
  • colon delivered b-vitamins
  • riboflavin
03

In context

Dysbiosis

189 studies on the registry are indexed under Dysbiosis; 66 are open to participants now.

This study's planned enrollment of 90 is above the median of 60 across 133 interventional studies indexed under Dysbiosis.

Browse Dysbiosis studies →

Lead sponsor

dsm-firmenich Switzerland AG is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals providing written for participation in the study and data processing
  2. Female and males between 50 and 70 years of age
  3. For females only: Menopausal as marked by at least 1 year since the last menstrual bleeding
  4. Individuals with a between 18.5 - 29.9 Kg/m2
  5. Individuals with stable body weight (≤5% change) over the past 3 months prior to V1
  6. Individuals with self-reported moderate bowel complaints in at least last 3 months prior to V1
  7. Individuals with GSRS score suggestive of moderate bowel complaints, as assessed at V1, for the average condition over the 4 last weeks (all GSRS items have to be answered at V1): • indigestion score 3-5 or constipation score 3-5 or diarrhoea score 3-5
  8. Individuals with a general good health, as determined by questioning, clinical examination and vital signs (blood pressure, pulse rate) by the investigator at V1
  9. Individuals willing to avoid consuming gut microbiome modulating dietary supplements, prebiotic, probiotic, synbiotic or fibre-rich supplements during the entire study duration
  10. Individuals willing to maintain current level of physical activity throughout the entire study duration
  11. If individuals are taking chronic medications (e.g., antihypertensive medications), they must be willing and expected to maintain the same dosage throughout the study

Exclusion criteria

Exclusion Criteria:

  1. Individuals who are hypersensitive/intolerant to any of the components of the product or the standardised diet addition (inulin)
  2. Individuals who have taken systemic antibiotics within the previous 3 months prior to Baseline (V2) or are expected to be taking any during the study
  3. Individuals who consumed microbiome modulating dietary supplements, prebiotic, probiotic, or fibre-rich supplements within 4 weeks prior to the baseline (V2)
  4. Individuals who are currently regularly using systemic , proton pump inhibitors, H2 blocker, antacids (however, sporadic use during the study if needed is allowed, but not within 8 hours before each visit), metformin if started less than 6 months prior to V1, or medication.
  5. Individuals who have a history of drug abuse in the previous 5 years and/or alcohol abuse at the time of enrolment (>11 units/week for women; >17 units/week for men; unit: approx. 125 mL of wine or similar / approx. 30 mL of spirits

    / approx. 280 mL beer or similar); Is currently in treatment for alcohol/substance abuse; Has been diagnosed with alcohol/substance abuse disorder)

  6. Individuals who are a smoker or vaper
  7. Individuals who are vegetarian or vegan
  8. Individuals who have made any major dietary changes in the past 3 months prior to Baseline (V2)
  9. Individuals who have planned major changes in the lifestyle (i.e., diet, dieting, exercise level, significant travel) during the duration of the study.
  10. Individuals who have a currently present active eating disorder
  11. Individuals with self-reported food allergy / intolerance (e.g., lactose, gluten, fructose), as determined by the study investigator
  12. Clinical significance for any of screening laboratory test results from the blood draw at V1, as per investigator's judgement
  13. Individuals with a self-reported fibre-rich regular diet, as per investigator's judgement
  14. Individuals who have a (self-reported) gastrointestinal disorder/disease (e.g., chronic/recurrent diarrhoea, inflammatory bowel disorder, irritable bowel syndrome, diverticulosis, stomach or duodenal ulcers, bile acid malabsorption) or previous gastrointestinal surgery (such as bariatric surgery, colon specific surgical interventions etc.), which in the opinion of the investigator would impact the study outcomes
  15. Individuals with GSRS assessed at V1 for the average condition over the 4 last weeks prior to V1 for any score (abdominal pain, reflux score, indigestion, constipation, diarrhoea) >5 (all GSRS items have to be answered at V1)
  16. Individuals who have severe or uncontrolled conditions such as type 2 diabetes (FBG ≥ 150 mg/dl from blood draw at V1), psychiatric disorder, respiratory or cardiac illness or any other condition which in the opinion of the investigator would impact the study outcomes
  17. Individuals who have a history of any gastrointestinal cancer
  18. Individuals who are severely immunocompromised
  19. Individuals with alarm features in the past 3 months prior to V1 such as unintentional weight loss (≤5% change), fever, anorectal problems, blood in stool, vomiting
  20. Individuals who, in the opinion of the investigator are considered to be poor attendees or unlikely for any reason to be able to comply with the study requirements
  21. If Individuals have been in a recent experimental study, this must have been completed not less than 30 days prior to this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Colon-delivered riboflavin

    This arm includes 10 mg of colon-delivered riboflavin

    Dietary Supplement: Colon-delivered riboflavin

  • Active comparator
    Conventional riboflavin

    This arm includes 10 mg of conventional riboflavin that will be absorbed in the upper small intestine and not reach the colon

    Dietary Supplement: Conventional riboflavin

  • Placebo comparator
    Placebo

    This arm includes 10 mg of microcrystalline cellulose

    Other: Microcrystalline Cellulose

Interventions

  • Dietary supplementColon-delivered riboflavin

    10 mg of colon-delivered riboflavin

  • Dietary supplementConventional riboflavin

    10 mg of conventional riboflavin

  • OtherMicrocrystalline Cellulose

    10 mg microcrystalline cellulose

06

What researchers measure

Primary outcomes

  1. Microbial alpha diversity

    Variation D28 - D0 in the faecal microbial alpha diversity (Observed richness, Inverse Simpson index, Shannon index)

    Time frame: 4 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd)

Secondary outcomes

  1. Microbial alpha diversity

    Variation D56 - D0 in the faecal microbial alpha diversity (Observed richness, Inverse Simpson index, Shannon index)

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

  2. Microbial composition

    Variations D28 - D0 and D56 - D0 in faecal microbial composition, assessed in terms of relative abundance of components at phylum, family, genus and species level and beta diversity (including Jaccard and Bray- Curtis dissimilarity indices)

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

  3. Faecal organic acid

    Variations D28 - D0 and D56 - D0 in faecal organic acid levels (acetate, propionate, butyrate, valerate, lactate)

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

  4. Faecal riboflavin

    Variations D28 - D0 and D56 - D0 in faecal concentrations of riboflavin

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

  5. Fecal redox potential

    Variations D28 - D0 and D56 - D0 in fecal redox potential level

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

  6. fecal pH

    Variations D28 - D0 and D56 - D0 in fecal pH

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

  7. Fecal calprotectin

    Variations D28 - D0 and D56 - D0 in fecal calprotectin

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

  8. Plasma Intestinal barrier markers

    Variations D28 - D0 and D56 - D0 in plasma intestinal barrier markers (LBP, I-FABP, zonulin and DAO)

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

  9. Gastrointestinal complaints

    Variations D28 - D0 and D56 - D0 in gastrointestinal complaints assessed by the gastrointestinal Symptom Rating Scale (GSRS) (reflux, abdominal pain, indigestion, diarrhoea, constipation)

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

  10. Stool consistency and frequency

    Variations D28 - D0 and D56 - D0 in stool consistency as assessed by Bristol Stool Form Scale (BSFS) and frequency

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

  11. Quality of life (Short-Form Health Survey (SF-36))

    Variations D28 - D0 and D56 - D0 in quality of life as assessed by the Short-Form Health Survey (SF-36)

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

  12. Investigational product (IP) perceived benefit

    Variations D28 - D0 and D56 - D0 in Investigational product (IP) perceived benefit assessed by a by a 5 point Likert scale

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

Other outcomes

  1. Plasma riboflavin concentrations

    Variations D28 - D0 and D56 - D0 in Plasma riboflavin concentrations

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

  2. Plasma immune markers

    Variations D28 - D0 and D56 - D0 in plasma immune markers (IL-6, IL-10, TNF alpha)

    Time frame: 8 weeks' daily consumption of 10 mg of colon delivered riboflavin (riboflavin-cd) including 5 g of dietary fiber inulin per day as a standardised addition to the subjects daily diet from week 4 to week 8.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.

Of 84 interventional studies with no phase under Dysbiosis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 20 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Aug 2026 → Mar 2027 and completion Sep 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Jul 30, 2025
StartActual
Jul 18, 2025
Primary completionEst.
Mar 2027was Aug 2026
CompletionEst.
Mar 2027was Sep 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Mar 2027
Nov 6, 2026
Study completion
Sep 2026→Mar 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Aug 2026→Mar 2027
    Study completion Sep 2026→Mar 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07093463
Collaborators
Analyze & Realize
Responsible party
Sponsor
First posted
Jul 30, 2025
Start date
Jul 18, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Veronika Bobb, Dr.
Contact
vbobb@a-r.com
+49 30 4000 8152
Liana Vismane, Dr
Contact
lvismane@a-r.com
+49 30 4000 8152

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion